APLF

Across TCGA pan-cancer cohorts, APLF mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated APLF data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher APLF mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated APLF expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where APLF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.476	0.779	.001	24	view →
CCRCC	DFS	Tertile	IV	0.908	0.173	.024	6	view →
PDAC	DFS	Quartile	All	0.588	0.355	.040	4	view →
LSCC	OS	Median	All	0.748	1.000	.006	2	view →
UCEC	DFS	Median	All	0.920	0.775	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

APLF–HNSC (DFS)

Open the HNSC breakdown →